References
Gronchi A, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clin Oncol. 2020; 38: 2178-86.
Gronchi A. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: results of the expanded cohort of myxoid liposarcoma of the randomized clinical trial from the Italian Sarcoma Group (ISG), the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG). J Clin Oncol. 2022; 40(16_suppl): 11508.
Pasquali S, Palmerini E, Quagliuolo V, Martin-Broto J, Lopez-Pousa A, Grignani G, et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: a Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. Cancer. 2022; 128: 85-93.
Tanaka K, Ozaki T. Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. Jpn J Clin Oncol. 2022; 52: 526-30.
Jernigan F, Branstrom A, Baird JD, Cao L, Dali M, Furia B, et al. Preclinical and early clinical development of PTC596, a novel small-molecule tubulin-binding agent. Mol Cancer Ther. 2021; 20: 1846-57.
Sanfilippo R. Trabectedin in advanced retroperitoneal well differentiated/dedifferentiated liposarcoma and leiomyosarcoma (TRAVELL): results of a phase 2 study from Italian sarcoma group (ISG). J Clin Oncol. 2022; 40(16_suppl): 11575.
Van Tine BA. A phase 1b study of unesbulin (PTC596) plus dacarbazine for the treatment of patients with locally recurrent, unresectable, or metastatic relapsed/refractory leiomyosarcoma. J Clin Oncol. 2022; 40(16_suppl): 11507.
Guo X. Efficacy and safety of eribulin in the treatment of advanced adult soft tissue sarcoma (STS): first real-world data in Chinese population. J Clin Oncol. 2022; 40(16_suppl): 11577.
Le Deley M-C. Activity of regorafenib in patients with non-adipocytic soft tissue sarcoma (NASTS): evaluation of heterogeneity of treatment effect on the updated analysis of pooled cohorts. J Clin Oncol. 2022; 40(16_suppl): 11555.
Movva S. Surufatinib in U.S. patients with soft tissue sarcoma. J Clin Oncol. 2022; 40(16_suppl): 11557.
Liu X, Xu J, Li F, Liao Z, Ren Z, Zhu L, et al. Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese Cohort Data from NCT03121846. Biomed Pharmacother. 2020; 122: 109587.
Chen TW-W. A phase Ib/Ⅱ study of the combination of lenvatinib (L) and eribulin (E) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER): efficacy updates. J Clin Oncol. 2022; 40(16_suppl): 11506.
Cornillie J, Wozniak A, Li H, Gebreyohannes YK, Wellens J, Hompes D, et al. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification. Clin Transl Oncol. 2020; 22: 546-54.
Yoshida K, Yokoi A, Yamamoto T, Hayashi Y, Nakayama J, Yokoi T, et al. Aberrant activation of cell-cycle-related kinases and the potential therapeutic impact of PLK1 or CHEK1 inhibition in Uterine leiomyosarcoma. Clin Cancer Res. 2022; 28: 2147-59.
Petitprez F, de Reyniès A, Keung EZ, Chen TW, Sun CM, Calderaro J, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020; 577: 556-60.
Italiano A, Bessede A, Pulido M, Bompas E, Piperno-Neumann S, Chevreau C, et al. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. Nat Med. 2022; 28: 1199-206.
Keung EZ-Y, Nassif EF, Lin HY, Lazar AJ, Torres KE, Wang W-L, et al. Randomized phase Ⅱ study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS): survival results after 2 years of follow-up and intratumoral B-cell receptor (BCR) correlates. J Clin Oncol. 2022; 40(16_suppl): LBA11501.
Lu J, Li T, Liao Z, Yu H, Zhao Y, Wu H, et al. The efficacies and biomarker investigations of antiprogrammed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma. Cancer Biol Med. 2021; 19: 910-30.
D’Angelo SP. Primary efficacy and safety of letetresgene autoleucel (lete-cel; GSK3377794) pilot study in patients with advanced and metastatic myxoid/round cell liposarcoma (MRCLS). J Clin Oncol. 2022; 40(16_suppl): 11500.
Kalbasi A, Siurala M, Su LL, Tariveranmoshabad M, Picton LK, Ravikumar P, et al. Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature. 2022; 607: 360-5.
Liao Z, Zhang C, Yang T, Liu H, Yang S, Li T, et al. Chemotherapy combined with recombinant Human Endostatin (Endostar) significantly improves the progression-free survival of stage IV soft tissue sarcomas. Front Oncol. 2022; 11: 778774.
Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, et al. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2022; 23: 1044-54.
Subbiah V, Cassier PA, Siena S, Garralda E, Paz-Ares L, Garrido P, et al. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Nat Med. 2022; 28: 1640-5.
Stacchiotti S, Maria Frezza A, Demetri GD, Blay JY, Bajpai J, Baldi GG, et al. Retrospective observational studies in ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. Cancer Treat Rev. 2022; 110: 102455.
